Nicholas H. Politan

Azenta Announces Actions to Support Ongoing Strategic and Governance Transformation

Retrieved on: 
Monday, November 13, 2023
Sale, Annual general meeting, CFO, Growth, Holding company, Rare-earth element, Management, Shareholder, BURLINGTON, Nicholas H. Politan, Azenta

Two of the Board's current independent directors will not be nominated to stand for re-election at the Annual Meeting.

Key Points: 
  • Two of the Board's current independent directors will not be nominated to stand for re-election at the Annual Meeting.
  • "We are thrilled to be able to announce these actions today and to welcome Didier and Martin to Azenta's Board as part of our ongoing transformation," said Steve Schwartz, President and CEO.
  • We also appreciate the thoughtful and constructive dialogue we have had with Politan Capital Management and our common focus on delivering value to Azenta stockholders.
  • In connection with today's announcements, Politan has withdrawn its notice to nominate candidates for election to the Board at the Annual Meeting.

Masimo Board of Directors Authorizes Appointment of Michelle Brennan as Sixth Director Pending Stockholder Approval of Board Expansion and Election of Company Nominees

Retrieved on: 
Friday, June 2, 2023
Hospitals, Health Technology, Health, Medical Devices, Shareholder, Interview, FOR, Distortion, Board of Governors of the United States Postal Service, Masimo, History, Cardinal Health, MASI, Nicholas H. Politan, Johnson & Johnson, Holding company

The Board of Directors of Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) today announced its commitment to appoint Michelle Brennan as the Company’s sixth director, pending stockholder approval of the proposal to expand the Board of Directors to seven and the election of the Company’s highly qualified director nominees, H Michael Cohen and Julie Shimer, Ph.D. Ms. Brennan was nominated by Politan Capital Management (“Politan”).

Key Points: 
  • The Board of Directors of Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) today announced its commitment to appoint Michelle Brennan as the Company’s sixth director, pending stockholder approval of the proposal to expand the Board of Directors to seven and the election of the Company’s highly qualified director nominees, H Michael Cohen and Julie Shimer, Ph.D. Ms. Brennan was nominated by Politan Capital Management (“Politan”).
  • Masimo stockholders do not need to vote for Ms. Brennan to secure her addition to the Board.
  • Stockholders should vote FOR Mr. Cohen and Dr. Shimer and FOR Board expansion on the WHITE proxy card.
  • Should stockholders approve the Board expansion and elect the Company’s nominees, Ms. Brennan would be appointed to the Board as a Class II director effective immediately following the Company’s Annual Meeting of Stockholders to be held on June 26, 2023, subject to Ms. Brennan’s willingness to serve.

Masimo Board of Directors Sets the Record Straight on False and Misleading Claims

Retrieved on: 
Thursday, June 1, 2023
Professional Services, Medical Devices, Health, Health Technology, Finance, General Health, Stork, IPO, FOR, Marketing, Confidentiality, NTM, Acquisition, Investment, The Wall Street Journal, Risk, MASI, Court, Total shareholder return, Compensated emancipation, Letter, Catalog, Stock dilution, Policy, Immunity, Consultant, Name, TAM, TSR, Employment, Disclosure, President's Management Advisory Board, SET, History, Government, Somatosensory system, Midas, Traction, Lead, Suggestion, Masimo, COVID, Entrust, Committee, MightySat-1, EPS, Holding company, Typesetting, Security (finance), Management, Tobacco, Property management, Life insurance, Private investigator, Audit, Cryptocurrency, Real estate, Nicholas H. Politan, DEI Holdings

The Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) Board of Directors today issued a letter to stockholders to set the record straight on the many highly misleading and inaccurate claims recently published by Politan Capital Management (“Politan”).

Key Points: 
  • The Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) Board of Directors today issued a letter to stockholders to set the record straight on the many highly misleading and inaccurate claims recently published by Politan Capital Management (“Politan”).
  • If shareholders approve the expansion of the Board, we will consider Ms. Brennan along with the other Board candidates and add the two best to Masimo’s Board.
  • On the other hand, Mr. Koffey is totally unqualified for the board of any medical technology company, much less Masimo’s Board.
  • Mr. Koffey has not demonstrated the trustworthy and principled behavior that Masimo shareholders should expect from their Board members.

Masimo Board of Directors Files Definitive Proxy and Issues Letter to Stockholders

Retrieved on: 
Friday, May 26, 2023
Hospitals, Health Technology, Health, Medical Devices, Stork, Failure, Marketing, Independent Board for Presbyterian Foreign Missions, Hospital, Acquisition, NTM, Patient, Risk, Align, Nasdaq Composite, Stock dilution, Research, Organization, Android (operating system), Apple, Growth, Behavior, Exercise, Pressure, Employment, History, SET, Capnography, Traction, Letter, Intuitive Surgical, Lead, Sound, Pyronia, OUS, Cryptocurrency, Renewable energy, Medical device, Fine chemical, Risk management, Pharmaceutical industry, Security (finance), Management, Medical imaging, COVID-19, Masimo, ResMed, Adjustment, Nicholas H. Politan, DEI Holdings

Rainbow®, Hospital AutomationTM, Radius PPG®, and other advanced technologies have given hospitals further reasons to standardize on Masimo SET®.

Key Points: 
  • Rainbow®, Hospital AutomationTM, Radius PPG®, and other advanced technologies have given hospitals further reasons to standardize on Masimo SET®.
  • Masimo has traditionally had seven directors, but due to retirements and Covid, the Board now has five.
  • Electing Quentin Koffey to the Board threatens Masimo’s mission, principles, strategy and leadership and jeopardizes the potential of your investment in Masimo.
  • Any vote on the blue proxy card will revoke your prior vote on a WHITE proxy card, and only your latest-dated proxy counts.

Politan Calls on Shareholders to Elect Independent Oversight to Masimo’s Board

Retrieved on: 
Tuesday, May 23, 2023
Other Professional Services, Professional Services, Finance, Lead, Louisiana-Pacific, Employment, MPC, LPX, CNC, Marathon Petroleum, Policy, CAH, Immunity, Research, History, SET, J&J, Somatosensory system, Cardinal Health, Elon Musk, Midas, Acquisition, Investment, Hearing, Annual general meeting, Growth, Johnson & Johnson, Health, LID, NYSE, Behavior, Management, Pharmaceutical industry, Film industry, Security (finance), Property management, Masimo, Nicholas H. Politan

The bottom 2% for “withhold” votes against Board members: Over the past decade, Masimo shareholders have withheld against Masimo directors at consistently high levels.

Key Points: 
  • The bottom 2% for “withhold” votes against Board members: Over the past decade, Masimo shareholders have withheld against Masimo directors at consistently high levels.
  • Create Lead Independent Director (LID) role; yet appoint Mr. Cohen as LID: While we strongly support independent leadership of Masimo’s Board, Mr. Cohen is the wrong choice.
  • Michelle is currently an independent director at Cardinal Health (NYSE: CAH) and recently served on the Board of Coupa Software (NASDAQ: COUP).
  • By electing us, shareholders will be adding to the Board independent, objective directors with the right skills and experience to help the Company realize its potential.

Politan Capital Management Takes Legal Action in Response to Masimo’s Attempts to Eliminate Stockholder Rights

Retrieved on: 
Friday, October 21, 2022
Professional Services, Legal, Finance, U.S. Securities and Exchange Commission, Medtronic, Masimo, NASDAQ, Investor, Security (finance), Confidentiality, Judgement, Partner (business rank), Sculptor Capital Management, Company, Amazon (company), MASI, Board, Alphabet Inc., Board of directors, CIO, Disclosure, Apple Inc., Holding company, Financial adviser, Management, Nicholas H. Politan

They require providing information that a nominating stockholder either does not have access to or is prohibited from disclosing due to confidentiality obligations.

Key Points: 
  • They require providing information that a nominating stockholder either does not have access to or is prohibited from disclosing due to confidentiality obligations.
  • Politan recently submitted a draft nomination notice with more than 100 pages of information about the firm and its Managing Partner, Quentin Koffey.
  • Quentin Koffey, Managing Partner and CIO of Politan, stated:
    We are taking this legal action because Masimo has left us no other option for preserving our rights as stockholders.
  • Masimos bylaws eliminate stockholders ability to nominate directors and restrict stockholder voting to only those candidates selected by the incumbents.